Connect with us

coronavirus

Coronavirus: EU-funded project launches a clinical trial for coronavirus treatment in Italy

SHARE:

Published

6 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Italian pharmaceutical regulatory agency, AIFA, has greenlighted a clinical trial for the use of Raloxifene in patients with mild symptoms caused by the coronavirus. In June 2020, the EU-funded consortium Exscalate4CoV using European supercomputing had announced that the registered generic drug used to treat osteoporosis could be an effective treatment for coronavirus. The European Commission supported the E4C Consortium with €3 million.

This is one of many examples of how the EU's research and innovation programme Horizon 2020 helps counter the coronavirus pandemic and develop new treatments. The clinical study should validate the safety and efficiency of Raloxifene in blocking the replication of the virus in cells, and thus hold up the progression of the disease. The study will take place at the National Institute for Infectious Diseases ‘L. Spallanzani' in Rome, Italy and will also involve the Humanitas Research Hospital in Milan.

In the initial phase, up to 450 participants in three separate treatment groups will be administered a 7-day treatment of Raloxifene capsules in a randomised sample. Exscalate4CoV, using a unique combination of high performance computing power and AI with biological processing, screened 400,000 molecules and specifically tested 7,000 molecules in vitro. You will find more information in the consortium press release.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending